好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Serum Activity of Angiotensin Converting Enzyme 2, a Potential Stroke Biomarker, is Decreased in the Acute Phase of Rat and Human Ischemic Stroke
Cerebrovascular Disease and Interventional Neurology
(-)
132
Authors/Disclosures
Doug Bennion (University of Florida)
PRESENTER
No disclosure on file
Christian A. Rosado, MD, FAAN No disclosure on file
No disclosure on file
No disclosure on file
Robert W. Regenhardt, MD, PhD Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genomadix. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. Dr. Regenhardt has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Buckley, Theroux, Kline, & Cooley Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.
No disclosure on file
Michael F. Waters, MD, PhD, FAAN (Mount Sinai Scholl of Medicine) Dr. Waters has nothing to disclose.
No disclosure on file